Department of Urology, University of California San Diego School of Medicine, La Jolla, CA, USA.
Department of Urology and Division of Experimental Oncology, Vita-Salute San Raffaele University, Milan, Italy.
World J Urol. 2019 Nov;37(11):2429-2437. doi: 10.1007/s00345-019-02650-9. Epub 2019 Feb 1.
To compare renal function and survival outcomes in patients with baseline chronic kidney disease (CKD) stage 2 undergoing partial (PN) or radical nephrectomy (RN), as nephron-sparing surgery is considered to be elective in this group.
Retrospective analysis of patients with CKD stage 2 and T1/T2 renal mass undergoing PN or RN from 2001 to 2015. Patients were stratified into substage CKD 2a or CKD 2b and analyzed between types of surgery. Primary outcome was overall survival (OS), eGFR < 45 at last follow-up was the secondary outcome. Multivariable analysis (MVA) was conducted for predictors of eGFR < 45 and OS. Kaplan-Meier analyses were conducted for freedom from eGFR < 45 and OS.
1213 patients analyzed (CKD 2a 609/CKD 2b 604) on MVA, RN (OR 3.68, p = 0.001) and CKD 2b (OR 3.3, p = 0.002) were independently associated with development of eGFR < 45 at last follow-up and RN (OR 3.76, p = 0.005) and eGFR < 45 (OR 2.51, p = 0.029) were associated with decreased OS. Kaplan-Meier analyses revealed that patients with CKD 2a/PN had the highest 5-year freedom from eGFR < 45 (94.3%) compared to CKD 2a/RN patients (91.5%), CKD2b/PN patients (87.6%) and CKD 2b/RN patients 82.0% (p < 0.001). Kaplan-Meier analyses for OS demonstrated that patients with CKD 2a/PN had significantly greater 5-year OS (97.6%) compared to CKD 2a/RN patients (95.2%), CKD 2b/PN patients (93.2%), and CKD 2b/RN patients (92.4%, p = 0.043).
Patients with baseline CKD stage 2, particularly CKD 2b and undergoing RN, are at increased risk of GFR < 45, which was associated with decreased OS. In patients with CKD 2b, a nephron-sparing strategy is indicated and should be prioritized when feasible.
比较基线慢性肾脏病(CKD)2 期患者行部分肾切除术(PN)或根治性肾切除术(RN)的肾功能和生存结局,因为保肾手术被认为是该组患者的首选。
回顾性分析 2001 年至 2015 年间接受 PN 或 RN 的 CKD 2 期和 T1/T2 肾肿瘤患者。患者按 CKD 2a 亚期或 CKD 2b 亚期分层,并分析手术类型。主要结局为总生存(OS),最后随访时 eGFR < 45 为次要结局。进行多变量分析(MVA)以预测 eGFR < 45 和 OS。进行 Kaplan-Meier 分析以评估 eGFR < 45 和 OS 的无失败率。
对 1213 例患者(CKD 2a 609/CKD 2b 604)进行 MVA,RN(OR 3.68,p=0.001)和 CKD 2b(OR 3.3,p=0.002)与最后随访时 eGFR < 45 的发生独立相关,RN(OR 3.76,p=0.005)和 eGFR < 45(OR 2.51,p=0.029)与 OS 降低相关。Kaplan-Meier 分析显示,与 CKD 2a/RN 患者(91.5%)、CKD2b/PN 患者(87.6%)和 CKD 2b/RN 患者(82.0%)相比,CKD 2a/PN 患者的 5 年 eGFR < 45 无失败率最高(p<0.001)。OS 的 Kaplan-Meier 分析表明,与 CKD 2a/RN 患者(95.2%)、CKD 2b/PN 患者(93.2%)和 CKD 2b/RN 患者(92.4%)相比,CKD 2a/PN 患者的 5 年 OS 显著更高(p=0.043)。
基线 CKD 2 期患者,特别是 CKD 2b 期和行 RN 的患者,eGFR < 45 的风险增加,这与 OS 降低有关。在 CKD 2b 患者中,建议采用保肾策略,在可行的情况下应优先考虑。